Shanghai, China, August 30, 2022 – Asieris Pharmaceuticals (stock code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced recently that the company has been included in the SSE STAR Biology and Medicine Index (the STAR Biology and Medicine Index for short), and the changes will take effect after the market closes on September 9, 2022.
After the screening for liquidity, the STAR Market Biomedicine Index, as one of the major industry-themed indices representing the STAR market, includes the stocks of 50 companies with large market capitalization in the biomedicine, biomedical engineering and other biological industries as index constituents, to reflect the overall performance of the securities of representative biomedical companies listed on the STAR market. Being included in the Index is therefore a testament to the outstanding scientific and technological strength of Asieris (688176.SH) as a whole.
Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.